Interestingly, only si GHR combined with sorafenib treatment continued cell growth decrease from S stage to G2M stage, suggesting that GHR inhibition combined with sorafenib prevented HCC cell progression from G stage to S and G2M stages. This evidence concerns the gene GHR and hepatocellular carcinoma.